Wall Street analysts expect Corium International Inc (NASDAQ:CORI) to report ($0.41) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Corium International’s earnings, with estimates ranging from ($0.42) to ($0.39). Corium International reported earnings of ($0.42) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.4%. The firm is expected to issue its next earnings results on Thursday, May 10th.
According to Zacks, analysts expect that Corium International will report full year earnings of ($1.43) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.19). For the next year, analysts forecast that the business will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.69) to ($0.84). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Corium International.
Corium International (NASDAQ:CORI) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.06. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. The business had revenue of $9.32 million for the quarter, compared to analyst estimates of $7.48 million.
A number of analysts have recently weighed in on CORI shares. HC Wainwright set a $15.00 price objective on shares of Corium International and gave the stock a “buy” rating in a research note on Friday, November 17th. ValuEngine upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 price objective on shares of Corium International in a research note on Friday, December 22nd. Zacks Investment Research upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research note on Tuesday, November 28th. Finally, Needham & Company LLC cut their price objective on shares of Corium International from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, December 26th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Corium International has a consensus rating of “Buy” and an average price target of $12.86.
Corium International (NASDAQ CORI) traded up $0.03 during trading hours on Friday, hitting $13.27. 311,200 shares of the stock were exchanged, compared to its average volume of 192,990. The firm has a market capitalization of $479.36, a price-to-earnings ratio of -8.45 and a beta of 1.59. Corium International has a 1 year low of $3.44 and a 1 year high of $13.93. The company has a debt-to-equity ratio of 5.91, a current ratio of 1.40 and a quick ratio of 1.34.
In other news, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were bought at an average price of $11.83 per share, for a total transaction of $595,640.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The shares were purchased at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in CORI. BlackRock Inc. grew its position in Corium International by 42.1% during the fourth quarter. BlackRock Inc. now owns 1,679,815 shares of the biopharmaceutical company’s stock valued at $16,143,000 after buying an additional 497,615 shares during the period. State Street Corp acquired a new stake in Corium International during the second quarter valued at $1,840,000. Emory University acquired a new stake in Corium International during the fourth quarter valued at $1,615,000. Opaleye Management Inc. grew its position in Corium International by 15.2% during the fourth quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock valued at $10,186,000 after buying an additional 140,000 shares during the period. Finally, Millennium Management LLC acquired a new stake in Corium International during the fourth quarter valued at $854,000. Institutional investors own 87.29% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.